Vanderbilt Ingram Cancer Center Archives
Chronic complications from immunotherapies more prevalent and persistent than previously shown among melanoma survivors
Aug. 8, 2023—A Vanderbilt study has found that chronic immunotherapy-related complications are more prevalent and persistent than previously shown among melanoma survivors.
Jul. 26, 2023—International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.
Jul. 20, 2023—Each passing day is precious for Deneen Eastridge, but a decade is a priceless gift. The Dallas resident came to Nashville recently to meet Trina Hughes, the stem cell donor who gave her the gift of life 10 years ago.
Jul. 19, 2023—Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.
Jun. 29, 2023—Vanderbilt investigators have revealed the mechanisms by which the chemokine receptor CXCR2, is associated with melanoma tumor formation and growth — a discovery that supports the continued development of drugs that inhibit the receptor’s activity.
Jun. 15, 2023—Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.
Jun. 15, 2023—A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.
Jun. 5, 2023—The expected course of a patient's cancer prognosis has traditionally been judged by its type, stage and microscopic aggressiveness, but patients with the same presentation can still have widely divergent outcomes. Researchers from Vanderbilt-Ingram Cancer Center have discovered that differences in tumor mutation burden are a major reason for this divergence.
May. 31, 2023—Vanderbilt research shows that a liquid biopsy-based multicancer early detection (MCED) test could detect 12 types of cancers, including low DNA-shedding cancers and early-stage cancers.
May. 11, 2023—Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.
Apr. 27, 2023—Vanderbilt is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
Apr. 26, 2023—The Vanderbilt-Ingram Cancer Center 24th Annual Scientific Retreat will be held from 8:30 am to 3 pm, May 23, in the Vanderbilt Student Life Center.